Cessatech A/S Share Price

Stocks

End-of-day quote NORDIC GROWTH MARKET 23/09/2026			5-day change	1st Jan Change
9.040 ^DKK	-2.16%		-3.62%	-43.36%

28/08	Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/08	Cessatech reports a slightly smaller operating loss	FW

Market Cap	30Cr 4.52Cr 3.97Cr 3.73Cr 3.41Cr 6.37Cr 432.76Cr 6.42Cr 45Cr 17Cr 220.64Cr 17Cr 17Cr 715.36Cr	P/E 2023	-3.77x	P/E 2024	-13.9x
Enterprise Value	28Cr 4.33Cr 3.8Cr 3.57Cr 3.27Cr 6.1Cr 414.7Cr 6.15Cr 43Cr 17Cr 211.43Cr 16Cr 16Cr 685.51Cr	EV / Sales 2023	-	EV / Sales 2024	7,77,32,546x
Free-Float	-	Yield 2023 *	-	Yield 2024	-

NORDIC GROWTH MARKETDKK

28/08	Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/08	Cessatech reports a slightly smaller operating loss	FW
28/08	Cessatech partner has released the first commercial batch of CT001 in the US	FW
27/08	Cessatech Releases CT001 For Shipment To Initial U.S. Hospitals And Commences Launch Activities	CI
24/07	CHMP says no to KemSu, review requested	FW
12/06	Cessatech partners with Rigshospitalet for CT004 development	FW
12/06	Cessatech A/S and University Hospital of Copenhagen, Rigshospitalet Enter Collaboration to Advance Intravenous Formulation of Melatonin for Post-Anaesthesia Delirium in Children	CI
28/05	Cessatech narrows losses	FW
28/05	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
27/02	Cessatech A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
27/02	Cessatech's Operating Loss Decreased in 2025	FW
27/02	Cessatech A/S Auditor Raises 'Going Concern' Doubt	CI
13/11	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

28/08	Second Quarter Report Q2-2026	AQ
27/08	CT001 ready for shipment to initial U.S. hospitals as launch activities commence	AQ
03/08	Cessatech: Cessatech – EMA initial KemSu/CT001 opinion Q&A and next steps	PU
03/08	Cessatech - EMA initial KemSu/CT001 opinion Q&A and next steps	AQ
24/07	Cessatech: Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu	PU

Manager	Title	Age	Since
Jes Trygved CEO	Chief Executive Officer	53	01/01/2020
Sarah Margaux Toft-Jørgensen DFI	Director of Finance/CFO	-	01/11/2025
Martin Juhl CTO	Chief Tech/Sci/R&D Officer	-	01/03/2022

Director	Title	Age	Since
Martin Olin CHM	Chairman	57	01/01/2022
Flemming Steen Jensen BRD	Director/Board Member	65	01/01/2020
Charlotte Videbaek BRD	Director/Board Member	64	01/01/2020